2013
DOI: 10.1016/j.biopsych.2012.11.029
|View full text |Cite
|
Sign up to set email alerts
|

Sustained Impairment of α2A-Adrenergic Autoreceptor Signaling Mediates Neurochemical and Behavioral Sensitization to Amphetamine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
15
0

Year Published

2013
2013
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 21 publications
(16 citation statements)
references
References 45 publications
1
15
0
Order By: Relevance
“…Increased DA tone is an established theory behind many models of drug addiction (65)(66)(67). However, a recent study highlights the key role of noradrenergic autoreceptor signaling in the persistent modifications induced by repeated drug administration (68). NE terminals can release DA, perhaps under conditions where dopamine ␤-hydroxylase located in vesicles of NE terminals is saturated (69).…”
Section: Discussionmentioning
confidence: 99%
“…Increased DA tone is an established theory behind many models of drug addiction (65)(66)(67). However, a recent study highlights the key role of noradrenergic autoreceptor signaling in the persistent modifications induced by repeated drug administration (68). NE terminals can release DA, perhaps under conditions where dopamine ␤-hydroxylase located in vesicles of NE terminals is saturated (69).…”
Section: Discussionmentioning
confidence: 99%
“…Our data suggest that blockade of α2A-adrenergic receptor can increase the level of NE in the PVN. In vivo dialysate measured by microdialysis showed α2A-adrenergic receptor agonist clonidine decreased the level of NE in the prefrontal cortex (Doucet et al, 2013), LC and cingulate cortex (Mateo et al, 2001), which also indicate that NE release might be highly dependent on the α2A-adrenergic receptors. Hence, the anomaly of α 2A -ARs maybe a physiopathology mechanism to trigger depressive disorder through direct or indirect effects to the secretion of NE in the PVN and the firing of LC noradrenergic neurons (Aoki et al, 1994; Nörenberg et al, 1997; Lee et al, 1998; Guiard et al, 2008; Wang et al, 2009).…”
Section: Discussionmentioning
confidence: 97%
“…Guanabenz/guanfacine is preferential for a2a, but clonidine and dexmedetomidine have equal affinity at a2 subtypes (Gobert et al, 1998). a2AR antagonists include yohimbine, efaroxan, BRL-44408 (2-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2,3-dihydro-1-methyl-1H-isoindole), dexefaroxan, idazoxan, and atipamezole (Dickinson et al, 1988;Villegier et al, 2003;Juhila et al, 2005;Jimenez-Rivera et al, 2006;Doucet et al, 2013). Yohimbine and atipamezole show equal affinities at all three receptor subtypes, but atipamezole has a 200-fold greater selectivity than yohimbine for the a2AR over the a1AR (Schwartz and Clark, 1998).…”
Section: Pharmacologic Compounds Targeting Adrenergic Receptorsmentioning
confidence: 99%
“…Antagonism of a2AR, on the other hand, which facilitates NE transmission by blocking autoreceptor function, increased both acute stimulant-induced locomotion (Dickinson et al, 1988;Villegier et al, 2003;Jimenez-Rivera et al, 2006) and sensitized responses (Doucet et al, 2013) in mice and rats. Conversely, the a2AR agonist clonidine, which suppresses NE release via autoreceptor stimulation, produced a decreased acute response to cocaine (Vanderschuren et al, 2003;JimenezRivera et al, 2006) and prevented amphetamine sensitization (Doucet et al, 2013).…”
Section: Stimulant-induced Locomotor Activitymentioning
confidence: 99%
See 1 more Smart Citation